Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients Single-arm phase II trials may not be appropriate for testing cytostatic ...
Generally, the randomization for phase II trials is between two regimens, tumor response is the end point of interest, and the goal is to determine whether one experimental regimen should be brought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback